Ortin Global Ltd
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.[1]
- Market Cap ₹ 9.57 Cr.
- Current Price ₹ 11.8
- High / Low ₹ 23.0 / 9.57
- Stock P/E
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding is low: 1.23%
- Promoter holding has decreased over last 3 years: -14.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Dividend Payout % |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | -4% |
5 Years: | -10% |
3 Years: | -20% |
1 Year: | -42% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Equity Capital |
Reserves |
Total Liabilities |
CWIP |
Investments |
Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Debtor Days |
Inventory Days |
Days Payable |
Cash Conversion Cycle |
Working Capital Days |
ROCE % |
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 2d
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct - 38th AGM held 30 Sep 2025; three resolutions passed; 199,162 votes cast.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep - 38th AGM on 30.09.2025; adopted FY2024-25 financials; director reappointment; secretarial auditor appointment.
-
Closure of Trading Window
25 Sep - Trading window closed from 01.10.2025 until 48 hours after unaudited results for quarter/half year ending 30.09.2025.
-
Notice Of 38Th AGM Of The Company Scheduled To Be Held On 30.09.2025
8 Sep - AGM on 30 Sept 2025; annual report filed; secretarial auditor appointed (FY2025-30), fee Rs.50,000.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
OLL is engaged in the manufacturing and trading of pharmaceuticals, drugs, and Intermediates and is also engaged in real estate.